BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37970740)

  • 1. Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
    Singh N; Staves J; Storry JR; Dinoso J; Renard C; Doshi P; Johnson LDS; Westhoff CM; Murphy MF
    Transfusion; 2023 Dec; 63(12):2377-2383. PubMed ID: 37970740
    [No Abstract]   [Full Text] [Related]  

  • 2. Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody).
    Tan M; Zacher N; French R; Borosak M; Lennard S; Le Viellez A; Benson S; Daly J
    Intern Med J; 2022 Dec; 52(12):2165-2171. PubMed ID: 36114660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
    Brierley CK; Staves J; Roberts C; Johnson H; Vyas P; Goodnough LT; Murphy MF
    Transfusion; 2019 Jul; 59(7):2248-2254. PubMed ID: 31183877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
    Murphy MF; Rajbhandary S; Carayiannis S; Cohn CS
    Transfusion; 2024 May; ():. PubMed ID: 38767410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
    Mei Z; Wool GD
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):797-811. PubMed ID: 31466605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal anti-CD47 interference in red cell and platelet testing.
    Velliquette RW; Aeschlimann J; Kirkegaard J; Shakarian G; Lomas-Francis C; Westhoff CM
    Transfusion; 2019 Feb; 59(2):730-737. PubMed ID: 30516833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two case reports involving therapeutic monoclonal anti-CD47 (Hu5F9-G4), it's effect on compatibility testing and subsequent selection of components for transfusion.
    Reyland L; Dwight M; Bullock T; Latham T; Lord K; Wardle A; Palmer D; Eggington J; Callaghan T; Seals D; Kulkarni S
    Transfus Med; 2020 Apr; 30(2):157-160. PubMed ID: 31914482
    [No Abstract]   [Full Text] [Related]  

  • 10. Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing.
    Wei H; Cui Y; Ren D; Jiang X; Fu W; Mu S; Yang L; Chen J
    Blood Transfus; 2024 Jan; 22(1):20-29. PubMed ID: 37847207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing.
    Kim TY; Yoon MS; Hustinx H; Sim J; Wan HI; Kim H
    Transfusion; 2020 Oct; 60(10):2399-2407. PubMed ID: 32820530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
    Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
    Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of new myeloma agents on the transfusion laboratory.
    Jones AD; Moayeri M; Nambiar A
    Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
    Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
    Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
    Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
    Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
    Sikic BI; Lakhani N; Patnaik A; Shah SA; Chandana SR; Rasco D; Colevas AD; O'Rourke T; Narayanan S; Papadopoulos K; Fisher GA; Villalobos V; Prohaska SS; Howard M; Beeram M; Chao MP; Agoram B; Chen JY; Huang J; Axt M; Liu J; Volkmer JP; Majeti R; Weissman IL; Takimoto CH; Supan D; Wakelee HA; Aoki R; Pegram MD; Padda SK
    J Clin Oncol; 2019 Apr; 37(12):946-953. PubMed ID: 30811285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?
    Bevel N; Thorpe M; Vanniasinkam T
    Vox Sang; 2024 May; ():. PubMed ID: 38705581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
    Qu T; Zhong T; Pang X; Huang Z; Jin C; Wang ZM; Li B; Xia Y
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD47 Agent Boosts Macrophage Activity in NHL.
    Cancer Discov; 2019 Jan; 9(1):7-8. PubMed ID: 30464001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.